Pages that link to "Q40883198"
Jump to navigation
Jump to search
The following pages link to Aldose reductase inhibitors: the end of an era or the need for different trial designs? (Q40883198):
Displaying 50 items.
- Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice (Q24530027) (← links)
- Ranirestat for the management of diabetic sensorimotor polyneuropathy (Q28241270) (← links)
- Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data (Q31121713) (← links)
- Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance (Q31383595) (← links)
- Cancer biomarker AKR1B10 and carbonyl metabolism. (Q33386598) (← links)
- Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors (Q33554440) (← links)
- Painful peripheral neuropathies (Q33673548) (← links)
- Dual Delivery of NGF and bFGF Coacervater Ameliorates Diabetic Peripheral Neuropathy via Inhibiting Schwann Cells Apoptosis (Q33717786) (← links)
- Painful diabetic neuropathy. (Q33728732) (← links)
- Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis (Q33848421) (← links)
- Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy (Q33854046) (← links)
- Diabetic neuropathy part 1: overview and symmetric phenotypes (Q33878023) (← links)
- Endothelial dysfunction in diabetes. (Q33959485) (← links)
- Nerve regeneration in diabetic neuropathy (Q34164146) (← links)
- Protein kinase C and the development of diabetic vascular complications (Q34570516) (← links)
- Polyol pathway and diabetic peripheral neuropathy (Q34800429) (← links)
- Measurement of somatic neuropathy for clinical practice and clinical trials (Q35087655) (← links)
- Diabetic neuropathy and nerve regeneration (Q35131671) (← links)
- Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes (Q35669992) (← links)
- Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? (Q35946085) (← links)
- Inhibition of aldose reductase by Gentiana lutea extracts (Q36111429) (← links)
- Transcriptome Profiles Using Next-Generation Sequencing Reveal Liver Changes in the Early Stage of Diabetes in Tree Shrew (Tupaia belangeri chinensis) (Q36741947) (← links)
- The therapeutic potential of gene transfer for the treatment of peripheral neuropathies (Q36762639) (← links)
- Glucose neurotoxicity (Q37038404) (← links)
- The effects of C-peptide on type 1 diabetic polyneuropathies and encephalopathy in the BB/Wor-rat (Q37147785) (← links)
- Synthesis and biological evaluation of new piplartine analogues as potent aldose reductase inhibitors (ARIs). (Q37380241) (← links)
- Aldose reductase meets histone acetylation: a new role for an old player. (Q37510190) (← links)
- Mechanism of diabetic neuropathy: Where are we now and where to go? (Q38213041) (← links)
- Painful diabetic neuropathy: an update (Q38247947) (← links)
- Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy (Q38905482) (← links)
- A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications (Q40740168) (← links)
- EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress (Q40794307) (← links)
- Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor (Q42050617) (← links)
- Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. (Q42165755) (← links)
- Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study (Q42621681) (← links)
- Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme (Q44252303) (← links)
- Effect of treatment with losartan on cardiovascular autonomic and large sensory nerve fiber function in individuals with diabetes mellitus: a 1-year randomized, controlled trial (Q44572357) (← links)
- Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats (Q44633752) (← links)
- Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors (Q44898251) (← links)
- A comparison of sural nerve conduction studies in patients with impaired oral glucose tolerance test (Q46912291) (← links)
- Mechanism of capsaicin inhibition of aldose reductase activity (Q48300940) (← links)
- Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations (Q48580864) (← links)
- Aldose reductase inhibitory activity studies of THERACURMIN. (Q50208438) (← links)
- Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications. (Q52658260) (← links)
- The aldo-keto reductase superfamily and its role in drug metabolism and detoxification (Q56760512) (← links)
- Curcumin, Cardiometabolic Health and Dementia (Q58699640) (← links)
- Treatment of painful diabetic neuropathy: a review of the most efficacious pharmacological treatments (Q58842272) (← links)
- Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex (Q73375409) (← links)
- Diabetic neuropathy (Q77098039) (← links)
- Administration of an aldose reductase inhibitor, ONO-2235, to streptozotocin-diabetic mice restores reductions of DRG neuronal attachment to extracellular matrix proteins in vitro (Q77356437) (← links)